Incidence of deep vein thrombosis among non‐ICU patients hospitalized for COVID‐19 despite pharmacological thromboprophylaxis

A remarkably high incidence of venous thromboembolism (VTE) has been reported among critically ill patients with COVID‐19 assisted in the intensive care unit (ICU). However, VTE burden among non‐ICU patients hospitalized for COVID‐19 that receive guideline‐recommended thromboprophylaxis is unknown.

[1]  Y. Hu,et al.  [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[2]  R. Claus,et al.  Postmortem Examination of Patients With COVID-19. , 2020, JAMA.

[3]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[4]  P. Demelo-Rodríguez,et al.  Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels , 2020, Thrombosis Research.

[5]  M. Aepfelbacher,et al.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[6]  R. Pola,et al.  Venous thromboembolism and heparin use in COVID-19 patients: juggling between pragmatic choices, suggestions of medical societies and the lack of guidelines , 2020, Journal of Thrombosis and Thrombolysis.

[7]  M. Ramakers,et al.  High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[8]  Yaolong Chen,et al.  Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines , 2020, Thrombosis and Haemostasis.

[9]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[10]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[11]  A. Shehata,et al.  The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control , 2020, Journal of clinical medicine.

[12]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[13]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[14]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[15]  Leonid Barski,et al.  Thromboembolic events in patients with severe pandemic influenza A/H1N1. , 2015, European journal of internal medicine.

[16]  W. Liles,et al.  Pandemic H1N1 influenza infection and vascular thrombosis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  P. Prandoni,et al.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score , 2010, Journal of thrombosis and haemostasis : JTH.

[18]  Yi Xiang-hua,et al.  Severe acute respiratory syndrome and venous thromboembolism in multiple organs. , 2010, American journal of respiratory and critical care medicine.

[19]  Lauren B. Smith,et al.  Autopsy findings in eight patients with fatal H1N1 influenza. , 2010, American journal of clinical pathology.

[20]  E. Kazerooni,et al.  Chest radiographic and CT findings in novel swine-origin influenza A (H1N1) virus (S-OIV) infection. , 2009, AJR. American journal of roentgenology.

[21]  F. Verschuren,et al.  Complete venous ultrasound in outpatients with suspected pulmonary embolism , 2009, Journal of thrombosis and haemostasis : JTH.

[22]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[23]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[24]  J. Harenberg,et al.  Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. , 1996, Haemostasis.